Who will buy Onyx? Well if you believe the article in Fierce Biotech today there will be a gaggle of potential suitors, in cluding but probably not limited to: Amgen, AstraZeneca, Bayer, BMS, Celgene, Gilead, Merck, Novartis and Pfizer.
In reading the article, one is led to believe that Amgen is still the odds on choice to win, but companies like Celgene and Gilead might make more attractive partners from the portfolio side of things, throwing in maybe BMS as well. The flashy new guys.
AZ and Merck seem like a couple of rich guys who are desperate what with failing pipelines and flagging R&D prospects. The old balding guys with expanding waste lines. Novartis is a rich guy who could buy if he wanted, and also get some savings by spinning off parts like Onyx's R&D and admin groups. Pfizer might be viewed similarly and is seen to potentially save additional costs by spinning off Nexavar to Bayer. Saavy traders.
Bayer is the old familiar fling who knows the about Onyx but perhaps isn't compfortable with the cost of acquisition as a result. Plus, Bayer might be able to gain control of Neaxvar cheaper without getting in a bidding war for the company and thus not stress itself out (being as conservative as it is). Your dear old Uncle Frederick. See Fierce Biotech.
Posted by Bruce Lehr July 2nd 2013.